Dawn Health, a leader in digital health, announced it has secured a €11.5 million funding round from its existing investors, Chr. Augustinus Fabrikker, the Export and Investment Fund of Denmark (EIFO), and Trifork.
What Dawn Health does: Since 2021, Dawn Health has been developing a platform designed to accommodate the needs and use cases of the pharmaceutical industry. And the Dawn Platform and Product Suite have already been widely adopted by five global industry leaders, including Merck and Novartis.
The Dawn Platform is now used in areas such as oncology, multiple sclerosis, and rare pediatric conditions like growth disorders. It helps patients manage their treatment, report symptoms, and stay in close contact with their healthcare team.
The Dawn Platform and Product Suite enables pharma companies, patients, and healthcare professionals to improve outcomes and patient care by utilizing advanced capabilities in AI, data, evidence generation, clinical integrations, personalization, and connected health. And by improving both data collection and analytics, these capabilities ultimately benefit patients and pharma companies alike, positioning the Dawn Platform as the foundation for therapy companions, disease management programs, and real-world evidence (RWE) solutions that enable the next generation of digital health.
This next phase reinforced Dawn Health’s position as a trusted partner to pharma companies, delivering valuable, scalable, regulatory-grade digital health products that evolve with the needs of modern medicine.
What the funding will be used for: The funding is aimed at supporting the company’s strategy to deliver its platform and product suite to global pharma companies through a SaaS model, while continuing to invest in further offerings within the Dawn Product Suite.
KEY QUOTES:
“Our ambition is to be the global leader in digital health, powering pharma’s next-generation products – and ultimately improving the lives of patients worldwide. This funding allows us to bring our proven platform to more markets and deepen our impact.”
Alexander Mandix Hansen, CEO of Dawn Health
“Since the major investment in December 2021, Dawn Health has grown its revenue significantly and expanded its footprint in global pharma. With more than 100 employees, unique solutions, and a strong regulatory infrastructure, we are prepared to further accelerate our growth.”
Chairman Lars Marcher
